Kyowa Kirin Co., Ltd.
PharmaTokyo, Japan, Japan · Est. 1949 · 3,700 employees
Kyowa Kirin is a Japanese pharmaceutical company focused on developing and commercializing innovative medicines in oncology, immunology, nephrology, and other therapeutic areas.
15
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
6
Indications↗
Distinct diseases across all programs
165
Clinical Trials↗
All sponsored trials (all statuses)
2
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
15 drugs in development
Phase 31
Phase 22
Phase 112
By Therapeutic Area
top 2
Oncology
213%
Cardiovascular
17%
R&D Momentum
45/100
Pipeline Velocity
6/100
Trial Completion Rate
90/100
Pipeline Concentration
66/100
Pipeline Freshness
73/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
- ↗Active in Oncology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Nov 4, 2026
Recruiting
Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
Oct 31, 2026
Active, not recruiting
Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia
Oct 27, 2026
Active, not recruiting
A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating the Safety and Tolerability of Intravenous KK2269 Monotherapy and Combination Therapy With Docetaxel in Adult Participants With Solid Tumors
Earlier
Oct 15, 2026TrialA Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema
Oct 15, 2026TrialA Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration
Oct 9, 2026TrialA Multicenter, Open-label, Single-arm, Phase 3 Study of KK8398 (Infigratinib) in Patients With Achondroplasia (AOBA Study)
Oct 6, 2026TrialA Japanese Phase 2 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)
Sep 30, 2026TrialA Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose or Multiple Ascending Dose Study of KK4277 in Healthy Volunteers, Patient With Systemic Lupus Erythematosus, and Patient With Cutaneous Lupus Erythematosus
4 more events
Sep 22, 2026TrialA Multicenter, Open-label, Phase 1/2, Dose-escalation and Subsequent Safety Extension Study of Subcutaneous KK8123 in Adult Patients With X-linked Hypophosphatemia
Aug 8, 2026TrialA Phase 1/2, Multicenter, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KK2430 in Participants With Hematologic Neoplasms
Aug 4, 20268-K8-K
Aug 3, 20268-KFORM 8-K
Details
Company Info
Company Overview
$9.5B
Mkt Cap
$2.2B
Revenue
—
Cash
CEOYoshihiko Hatanaka
Founded1949
Employees3,700
HQTokyo, Japan, Japan
Websitekyowakirin.com/
LinkedInCompany Page
Therapeutic Focus
oncologyimmunologynephrologyhematology
Recent SEC Filings
8-KAug 4, 2026
8-K
8-KAug 3, 2026
FORM 8-K
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular
Cardiovascular
Essential Hypertension
KK3910Phase 1
Oncology
Unknown / Other
Achondroplasia
KK8398Phase 3
Relapsed or Refractory
KK2845_1Phase 1
KK2845_2Phase 1
KK2845_3Phase 1
KK2845_4Phase 1
KK2845_5Phase 1
KK2845_6Phase 1
KK2845_alternative_1Phase 1
KK2845_alternative_2Phase 1
Kk2845_7Phase 1
Kk2845_8Phase 1
Regulatory
Regulatory Timeline
19971 event
FDAMay 29
Fareston — FARESTON
Application NDA020497 (NDA)
20182 events
FDAAug 8
POTELIGEO — POTELIGEO
Application BLA761051 (BLA)
FDAApr 17
CRYSVITA — CRYSVITA
Application BLA761068 (BLA)
20192 events
FDAAug 27
Nourianz — NOURIANZ
Application NDA022075 (NDA)
FDAAug 27
Nourianz — NOURIANZ
Application NDA022075
20262 events
SECAug 4
8-K
Accession: 0000277135-26-000076
SECAug 3
FORM 8-K
Accession: 0001104659-26-089478
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)